Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kramar A et al. - Several multistage or group sequential statistical methods have been developed for defining stopping rules in terms of efficacy in phase II and III clinical trials, but they rely on interim analyses after the inclusion of a fixed number of patients. These methods, however, need to be adapted for the evaluation of serious adverse events (SAEs), which can occur relatively early in the trial. A high frequency of their occurrence may require the trial to close early.

Related Articles

Increase in Quality, but Not Quantity, of Clinical Trials in Acute Pain: 1992 Versus 2007
Anesthesia & Analgesia, 10/21/09    Relevance Score: 69%

Cytokinetics Announces Advancement of CK-2017357 in Phase I Clinical Trials
Cytokinetics, 11/10/09    Relevance Score: 68%

Methodological aspects of lung cancer clinical trials in the era of targeted agents
Lung Cancer, 11/03/09    Relevance Score: 68%

Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial
Boston Scientific, 10/06/09    Relevance Score: 68%

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data
Cancer Chemotherapy and Pharmacology, 10/05/09    Relevance Score: 68%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address